Thursday, March 27, 2025
spot_img

CVB Financial Corp. Announces 142nd Consecutive Quarterly Cash Dividend

Ontario, CA, March 19, 2025 (GLOBE NEWSWIRE) — CVB Financial Corp. (NASDAQ: CVBF) (the “Company”) announced a twenty cent ($0.20) per share cash dividend with respect to the first quarter of 2025. This dividend was approved at the Company’s regularly scheduled Board of Directors meeting held on March 19, 2025. The quarterly dividend will be payable on or about April 16, 2025 to shareholders of record as of April 2, 2025.

“We are pleased to announce our 142nd consecutive quarterly cash dividend paid to our shareholders,” said David A. Brager, President and Chief Executive Officer.

Corporate Overview
CVB Financial Corp. (“CVBF”) is the holding company for Citizens Business Bank. CVBF is one of the 10 largest bank holding companies headquartered in California with greater than $15 billion in total assets. Citizens Business Bank is consistently recognized as one of the top performing banks in the nation and offers a wide array of banking, lending and investing services with more than 60 banking centers and three trust office locations serving California.

Shares of CVB Financial Corp. common stock are listed on the NASDAQ under the ticker symbol “CVBF”. For investor information on CVBF, visit our Citizens Business Bank website at www.cbbank.com and click on the “Investors” tab.

Safe Harbor
Certain matters set forth herein may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including forward-looking statements relating to the Company’s current business plans and expectations, growth projections, and our future financial position and operating results. Words such as “will likely result, “aims”, “anticipates”, “believes”, “could”, “estimates”, “expects”, “hopes”, “intends”, “may”, “plans”, “projects”, “seeks”, “should”, “will” and variations of these words and similar expressions help to identify these forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results, performance and/or achievements to differ materially from those projected. These risks and uncertainties include, but are not limited to, all the risk factors set forth in the Company’s public reports, including its Annual Report on Form 10-K for the year ended December 31, 2024, and particularly the discussion of risk factors within that document. The Company does not undertake, and specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences or unanticipated events or circumstances after the date of such statements except as required by law.

Contact: David A. Brager
President and Chief Executive Officer
(909) 980-4030

Powered by SlickText.com

Hot this week

Atmus Filtration’s Path To Growth: Analyst Highlights Strong Financials, Tariff Pricing Power

Atmus Filtration Technologies Inc. ATMU has strong growth potential,...

Soleno Shares Are Up Today: What’s Going On?

Soleno Therapeutics, Inc. SLNO shares are trading higher Thursday...

Ultragenyx Stays On JPMorgan’s Focus List As Analyst Highlights Strong Long-Term Positioning

JPMorgan on Thursday shared updated thoughts on Ultragenyx Pharmaceutical Inc’s...

Candel Therapeutics Shares Are Down Today: What’s Going On?

Candel Therapeutics, Inc. CADL shares are are trading lower...

Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug

The Japanese Ministry of Health, Labour and Welfare on...

Topics

Atmus Filtration’s Path To Growth: Analyst Highlights Strong Financials, Tariff Pricing Power

Atmus Filtration Technologies Inc. ATMU has strong growth potential,...

Soleno Shares Are Up Today: What’s Going On?

Soleno Therapeutics, Inc. SLNO shares are trading higher Thursday...

Ultragenyx Stays On JPMorgan’s Focus List As Analyst Highlights Strong Long-Term Positioning

JPMorgan on Thursday shared updated thoughts on Ultragenyx Pharmaceutical Inc’s...

Candel Therapeutics Shares Are Down Today: What’s Going On?

Candel Therapeutics, Inc. CADL shares are are trading lower...

Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug

The Japanese Ministry of Health, Labour and Welfare on...

Chemomab Therapeutics’ Touts Positive Data From Experimental Drug For Chronic Liver Disease

Chemomab Therapeutics Ltd. CMMB on Thursday released results from the...

Vertical Aerospace Unfairly Undervalued, Says Bullish Analyst

D. Boral Capital analyst Jesse Sobelson initiated coverage on...

Petrus Resources Announces Monthly Activity Update

CALGARY, Alberta, March 27, 2025 (GLOBE NEWSWIRE)...
spot_img

Related Articles

Popular Categories

spot_img